• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Acadia Pharmaceutica (NQ: ACAD )

    17.66 +0.46 (+2.67%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,533,672
    Open 17.10
    Bid (Size) 17.70 (3)
    Ask (Size) 17.81 (3)
    Prev. Close 17.20
    Today's Range 17.10 - 17.97
    52wk Range 14.15 - 32.59
    Shares Outstanding 162,625,379
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
    From Acadia Pharmaceuticals Inc.
    Via Business Wire

    Performance

    YTD
    -42.77%
    -42.77%
    1 Month
    +21.37%
    +21.37%
    3 Month
    +15.50%
    +15.50%
    6 Month
    +16.34%
    +16.34%
    1 Year
    -20.45%
    -20.45%

    More News

    Read More
    Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    Expert Outlook: ACADIA Pharmaceuticals Through The Eyes Of 5 Analysts
    Via Benzinga
    A Closer Look at 13 Analyst Recommendations For ACADIA Pharmaceuticals
    Via Benzinga
    Critical Insights From ACADIA Pharmaceuticals Analyst Ratings: What You Need To Know
    Via Benzinga
    Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    What's Going On With ACADIA Pharmaceuticals Stock?
    Via Benzinga
    Expert Ratings For ACADIA Pharmaceuticals
    Via Benzinga
    Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    Jim Cramer Believes In Dell CEO, Doesn't Like B&G Foods
    Via Benzinga
    Ryan Reynolds Announces More to Parkinson’s® Campaign
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'
    Via Investor's Business Daily
    Topics Earnings
    Exposures Financial
    Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
    Via Benzinga
    Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
    From Acadia Pharmaceuticals, Inc.
    Via Business Wire
    3 Sorry Pharma Stocks to Sell in May While You Still Can
    Via InvestorPlace
    After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
    Via Benzinga
    Topics Data Breach
    Exposures Information Security
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.